04042nam a22005535i 4500001001800000003000900018005001700027007001500044008004100059020003700100024003500137050001400172072001600186072002300202072001500225245014500240250001800385264007200403300006600475336002600541337002600567338003600593347002400629505104900653520103501702650003702737650002502774650003002799650002102829650002702850650002102877650002602898650002502924650004602949650002102995650002603016650002103042700008503063700008103148710003403229773002603263776003603289776003603325776003603361856004603397912001403443912001403457999001703471978-981-97-5077-1DE-He21320251030112930.0cr nn 008mamaa240901s2024    si |    s    |||| 0|eng d  a97898197507719978-981-97-5077-17 a10.1007/978-981-97-5077-12doi 4aRS400-431 7aPSB2bicssc 7aSCI0130402bisacsh 7aPNB2thema10aPROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeuticsh[electronic resource] /cedited by Mukesh Nandave, Priti Jain.  a1st ed. 2024. 1aSingapore :bSpringer Nature Singapore :bImprint: Springer,c2024.  aXXII, 385 p. 68 illus., 55 illus. in color.bonline resource.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda0 a1. Understanding the Ubiquitin Proteasome System - History and Revolution -- 2. PROTACs: Principles and Mechanisms -- 3. Structural Considerations and Chemistry of PROTAC -- 4. Advantages and Disadvantages of PROTACs -- 5. Novel Technologies in PROTAC Design -- 6. Future of trends in the design and development of PROTAC -- 7. Global Regulatory Requirements Applicable for PROTACs -- 8. Tissue-Specific Targeting Strategies with PROTAC Technology -- 9. Clinical Development OF PROTACs -- 10. Toxicological Aspects of PROTACs -- 11. PROTACs in the management of Prostate Cancer -- 12. Exploring the Role of PROTACs for the Treatment of Breast Cancer -- 13. Role of PROTACs in Hematological Malignancies -- 14. Artificial Intelligence and Machine Learning for Exploring PROTAC in Underutilized Cells -- 15. PROTACs in Treatment of Glioma -- 16. Proteolysis Targeting Chimera (PROTACs) an Attractive Technology in CVD Therapeutics: Opportunities and Challenges -- 17. Delivery systems - miniaturised PROTAC, Nano PROTAC, Aptamer-based RNA PROTAC.  aThis book is a comprehensive coverage of the ubiquitin-proteasome system and its involvement in cancer progression, and the application of PROTACs in different types of cancer treatment. The book discusses a unique perspective and comprehensive knowledge of the potential of PROTACs to transform cancer therapies. It provides an overview of the history, mechanisms, chemistry, design considerations, and different technologies involved in PROTACs. Additionally, it explains the ubiquitin-proteasome system, its impact on various diseases, and the principles and mechanisms of UPS. The book also describes the chemistry and design aspects of PROTACs and their role in various types of cancers. Finally, it covers the pharmaceutics aspect of formulation design, global requirements, and toxicological aspects of PROTACs. This book is targeted at cancer researchers, medical oncologists, bioinformatics, computational biologists, pharmacologists, medicinal chemists, formulation scientists, regulatory authorities, and policy makers. 0aPharmaceutical chemistry.967843 0aPharmacology.967844 0aPharmacovigilance.974275 0aOncology.970760 0aDrug delivery systems. 0aPharmacy.96466614aPharmaceutics.96784624aPharmacology.96784424aDrug Safety and Pharmacovigilance.97427624aOncology.97076024aDrug Delivery.96942924aPharmacy.9646661 aNandave, Mukesh.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt9747241 aJain, Priti.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt9835042 aSpringerLink (Online service)0 tSpringer Nature eBook08iPrinted edition:z978981975076408iPrinted edition:z978981975078808iPrinted edition:z978981975079540uhttps://doi.org/10.1007/978-981-97-5077-1  aZDB-2-SME  aZDB-2-SXM  c63005d63005